Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound yew capsule is a Chinese patent medicine (CPM) primarily used as an adjuvant or maintenance therapy for various malignancies, including non-small cell lung cancer (NSCLC), breast cancer, and ovarian cancer. The formulation is composed of extracts from *Taxus chinensis* (Chinese yew), which contains natural taxanes such as paclitaxel, along with other traditional Chinese medicinal herbs including *Panax ginseng*, *Astragalus membranaceus*, and *Ganoderma lucidum*. The taxane component acts by stabilizing microtubules, thereby inhibiting mitosis and inducing apoptosis in cancer cells. The additional herbal components are intended to enhance immune function and mitigate the side effects of chemotherapy, aligning with the TCM principle of "strengthening the body's resistance and eliminating pathogenic factors." It is frequently evaluated in China for patients with "Qi deficiency and phlegm stasis" syndromes to improve quality of life and prolong survival.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound yew capsule.